Trials
2 active
2 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “triamcinolone 40mg/ml or topical clobetasol 0.05% with nepafenac 0.3% QD for 14 days”In the company’s words, NCT07276802 on ClinicalTrials.gov
- Tested for
- Post Cataract Surgery
- Main trialPhase 4
- “A self-controlled, prospective clinical study of the safety, clinical efficacy, and patient acceptance of subconjunctival delivery of triamcinolone 40 mg/mL (Triesence) at the conclusion of cataract surgery or topical clobetasol 0.05 (Byqlovi) BID for 14 days, with intracameral moxifloxacin 0.5%, and topical nepafenac 0.3% (Ilevro) for 14 days, as compared to traditional topical postoperative prednisolone acetate 1% QID, moxifloxacin 0.5% drops QID, and ketorolac 0.5% QID in controlling postoperative pain and inflammation in subjects undergoing sequential bilateral cataract surgery.”In the company’s words, NCT07276802 on ClinicalTrials.gov
Coming up1
- 31 DecPhase 4 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Not yet recruiting | 31 Dec 2026 | The TRIBECA Study (TRIessence/Byqlovi for Easier CAtaract Surgery) | |
| Phase 4Authorised | not given | Frozen shoulder – the role of physiotherapy |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026